Stock ALLO ALLOGENE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Allogene Therapeutics, Inc.

Equities

ALLO

US0197701065

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 01:27:34 2024-07-11 pm EDT 		5-day change 1st Jan Change
2.695 USD +12.76% Intraday chart for Allogene Therapeutics, Inc. +26.89% -16.20%
Jul. 01 Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma CI
Jun. 20 Allogene Therapeutics Inc. Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel as Part of First Line Treatment for Patients with Large B-Cell Lymphoma CI

Business Summary

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on four core programs: Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia (CLL), Autoimmune Disease and Renal Cell Carcinoma. It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL and CLL. Its pipeline also includes ALLO-316, ALLO-329 and ALLO-647.

Number of employees: 233

Sales per Business

USD in Million2022Weight2023Weight Delta
Allogeneic T Cell Therapies
100.0 %
0 100.0 % 0 100.0 % -60.91%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 100.0 % 0 100.0 % -60.91%

Managers

Managers TitleAgeSince
Joshua Kazam FOU
 Founder 47 17-10-31
David Chang FOU
 Founder 64 18-03-31
Geoffrey Parker DFI
 Director of Finance/CFO 59 23-10-15
Lillian Smith CMP
 Compliance Officer 52 23-03-31
Zachary Roberts CTO
 Chief Tech/Sci/R&D Officer 46 23-01-02
Timothy Moore CTO
 Chief Tech/Sci/R&D Officer 62 23-03-31
Earl Douglas CMP
 Compliance Officer 61 23-08-13
Jack Chen AUD
 Comptroller/Controller/Auditor - -
Susan R. Lundeen-Smuck HRO
 Human Resources Officer 58 22-05-01
Christine Cassiano LAW
 General Counsel - 18-02-28

Members of the board

Members of the board TitleAgeSince
David Bonderman BRD
 Director/Board Member 81 18-04-30
Joshua Kazam FOU
 Founder 47 17-10-31
Arie Belldegrun FOU
 Founder 74 17-10-31
Vicki Sato BRD
 Director/Board Member 75 21-07-29
Todd Sisitsky BRD
 Director/Board Member 52 18-03-31
Stephen Mayo BRD
 Director/Board Member 62 22-07-11
Elizabeth Barrett BRD
 Director/Board Member 61 21-07-29
Deborah Messemer BRD
 Director/Board Member 66 18-09-27
Owen Witte BRD
 Director/Board Member 74 18-03-31
David Chang FOU
 Founder 64 18-03-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 208,384,002 153,115,957 ( 73.48 %) 0 73.48 %

Shareholders

NameEquities%Valuation
Fidelity Management & Research Co. LLC
12.15 %
25,363,798 12.15 % 59 M $
PFIZER, INC.
10.55 %
22,032,040 10.55 % 51 M $
TPG Group Holdings (SBS) Advisors, Inc.
8.964 %
18,716,306 8.964 % 44 M $
Arie Belldegrun
4.837 %
10,099,279 4.837 % 24 M $
STATE STREET CORPORATION
4.399 %
9,184,011 4.399 % 21 M $
BlackRock Advisors LLC
4.259 %
8,892,356 4.259 % 21 M $
Vanguard Fiduciary Trust Co.
3.931 %
8,207,564 3.931 % 19 M $
David Chang
3.699 %
7,723,302 3.699 % 18 M $
PRIMECAP Management Co.
2.610 %
5,448,386 2.610 % 13 M $
JPMorgan Investment Management, Inc.
2.482 %
5,181,979 2.482 % 12 M $

Company contact information

Allogene Therapeutics, Inc.

210 East Grand Avenue

94080-4811, South San Francisco

+

http://www.allogene.com
address Allogene Therapeutics, Inc.(ALLO)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Allogene Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
2.39 USD
Average target price
11.24 USD
Spread / Average Target
+370.23%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ALLOGENE THERAPEUTICS, INC. Stock Allogene Therapeutics, Inc.
-25.55% 499M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+20.82% 127B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+21.96% 116B
ARGENX SE Stock argenx SE
+25.30% 27.69B
BIONTECH SE Stock BioNTech SE
-22.97% 19.62B
GENMAB A/S Stock Genmab A/S
-18.10% 16.26B
BEIGENE, LTD. Stock BeiGene, Ltd.
-19.03% 15.49B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+11.66% 14.81B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-48.41% 14.39B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+54.78% 14.11B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ALLO Stock
  4. Company Allogene Therapeutics, Inc.